HD Labs Retatrutide 10mg is a research-grade triple-agonist peptide (GLP-1/GIP/glucagon, LY3437943 analogue) sold in South Africa as a non-registered research chemical. Researchers looking to buy retatrutide peptide South Africa-side will find local HD Labs SKUs priced in the R50–R70 per mg band based on 2025–2026 ZAR listings for the 32 mg vial (R1,600 at Health and Fitness ZA; R1,800 at Ignite Muscle). Retatrutide remains unscheduled by SAHPRA and unregistered as a medicine, so all local supply is positioned strictly "not for human use". Last updated: March 2026.
Key Takeaways
- Retatrutide is a triple-agonist peptide (GLP-1/GIP/glucagon) supplied in South Africa as a non-registered research chemical only
- The 10 mg vial corresponds to the 12 mg dose arm that produced approximately 24% mean weight reduction at 48 weeks in the 2023 NEJM Phase 2 trial
- Current ZAR pricing runs R50–R70 per mg; the 10 mg presentation is research-relevant for benchmarking against published Phase 2 efficacy data
- Retatrutide differs from tirzepatide by one receptor target: the added glucagon component drives energy-expenditure pathways absent in dual agonists
- No regulatory approval exists in South Africa or globally as of March 2026; all local supply carries explicit research-use-only labelling
Why the 10 mg vial matters for SA procurement
The 10 mg presentation corresponds to the 12 mg arm that produced approximately 24% mean weight reduction at 48 weeks in the 2023 NEJM Phase 2 obesity trial (NCT04881760). That dose tier is the most research-relevant for laboratories benchmarking against published triple-agonist data, it was the highest-dose cohort tested in the primary Phase 2 efficacy study.
What Is HD Labs Retatrutide 10mg?
HD Labs Retatrutide 10mg is a lyophilised vial of synthetic retatrutide (development code LY3437943, originated by Eli Lilly) supplied for in vitro and preclinical research use only, distributed in South Africa under the HD Labs brand at the 10 mg fill weight. The compound is a 39-amino-acid acylated peptide with a C20 diacid fatty-acid moiety conjugated via a γGlu-2xOEG linker. This conjugation extends plasma half-life to roughly six days in published pharmacokinetic work (Coskun et al. 2022, Journal of Medicinal Chemistry), which allows the compound to remain active over a weekly dosing interval in clinical protocols.
Molecular identity
Retatrutide is a single-molecule triple receptor agonist at the GLP-1 receptor (GLP-1R), the GIP receptor (GIPR), and the glucagon receptor (GcgR), with a molecular weight of approximately 4.7 kDa. HD Labs supplies the peptide as a white lyophilised powder requiring reconstitution in bacteriostatic water prior to laboratory use.
Regulatory positioning and pricing
The 10 mg vial is sold strictly as a non-registered research chemical and carries no SAHPRA registration. Current ZAR pricing is displayed on the live product listing within the retatrutide product category. Researchers benchmarking against the dual GLP-1/GIP agonist class can reference the Body Pharm Tirzepatide 30 Pen listing on the same site for mechanistic comparison.
Triple Agonist Mechanism: GLP-1, GIP, and Glucagon
Retatrutide simultaneously activates three incretin and counter-regulatory receptors, GLP-1R, GIPR, and GcgR, as a single peptide. This produces additive metabolic effects that neither mono- nor dual-agonists reproduce in preclinical models. The molecular design, reported by the Eli Lilly chemistry team in Coskun et al. 2022, balances receptor potency ratios deliberately: GIPR activity is tuned higher than glucagon activity to constrain hyperglycaemic risk from the GcgR component, maintaining safety margins in preclinical testing.
GLP-1 receptor: appetite and insulin secretion
GLP-1R activation in pancreatic β-cells stimulates glucose-dependent insulin secretion. GLP-1R signalling in hypothalamic and brainstem neurons suppresses appetite and slows gastric emptying. This is the same axis exploited by semaglutide and the GLP-1 arm of tirzepatide.
GIP receptor: insulin potentiation and adipose handling
GIPR activation potentiates β-cell insulin response to nutrient loads and modifies adipose tissue lipid buffering, improving postprandial substrate handling. Adding GIPR agonism to GLP-1 agonism is what distinguishes the Body Pharm Tirzepatide 30 Pen (dual GLP-1/GIP) from earlier GLP-1 monoagonists.
Glucagon receptor: hepatic output and energy expenditure
GcgR activation increases hepatic glucose output. More relevant to the obesity phenotype, it raises resting energy expenditure and promotes hepatic lipid oxidation. This third arm is what separates retatrutide from tirzepatide. It is the proposed pharmacological basis for the approximately 24% mean body-weight reduction observed at the 12 mg dose over 48 weeks in Jastreboff et al. 2023 (NEJM), and for the liver-fat reductions reported in the Phase 2a MASLD study (Sanyal et al. 2024, Nature Medicine).
Researchers comparing compounds across the retatrutide product category should treat the GcgR arm as the defining variable when designing in vitro assays that need to distinguish triple- from dual-agonist responses.
Retatrutide vs Tirzepatide vs Semaglutide: Receptor Comparison
The defining difference is receptor breadth: semaglutide engages one incretin receptor, tirzepatide engages two, and retatrutide engages three. The glucagon receptor arm is the mechanistic feature unique to retatrutide, which is why it produces a distinct pharmacological profile in preclinical models.
| Compound | Receptors Targeted | Key Mechanistic Differentiator |
|---|---|---|
| Semaglutide | GLP-1 | Appetite suppression and glucose-dependent insulin secretion via a single incretin pathway |
| Tirzepatide | GLP-1 + GIP | Adds GIPR-mediated insulin potentiation and adipose lipid buffering on top of GLP-1 effects |
| Retatrutide | GLP-1 + GIP + GcgR | Adds glucagon-receptor agonism, implicated in raised resting energy expenditure and hepatic lipid oxidation |
Why the glucagon arm matters
GcgR agonism separates retatrutide from the Body Pharm Tirzepatide 30 Pen and from semaglutide-class compounds. It introduces an energy-expenditure pathway that does not exist in dual or mono agonists, and is the proposed pharmacological basis for retatrutide's larger weight-reduction signal and its activity in MASLD/MASH models. Researchers designing assays across the retatrutide product category should treat GcgR engagement as the discriminating endpoint.
Phase 2 weight-reduction figures (not head-to-head)
Published Phase 2 efficacy signals are as follows:
- Semaglutide produced approximately 15% mean body-weight reduction in the 2021 STEP programme
- Tirzepatide produced approximately 22.5% at the top dose in the 2022 SURMOUNT-1 trial
- Retatrutide produced approximately 24.2% at the 12 mg dose over 48 weeks in Jastreboff et al. 2023 (NEJM)
These figures come from separate trials with different populations, durations, and endpoints. Direct numerical comparison is not valid evidence of superiority. No head-to-head Phase 2 or Phase 3 clinical trial between retatrutide and tirzepatide has been published or registered as of early 2026.
2023–2026 Clinical Research Summary
The highest-grade public evidence for retatrutide as of early 2026 remains the Phase 2 obesity trial published by Jastreboff et al. 2023 (NEJM) on 26 June 2023. The 48-week, double-blind, randomised study (ClinicalTrials.gov NCT04881760) tested doses from 0.5 mg to 12 mg weekly against placebo. The primary endpoint was mean percentage change in body weight at week 48. The 12 mg cohort recorded approximately 24.2% mean weight reduction versus placebo, with no plateau evident at the end of titration, suggesting the dose-response curve had not yet flattened and that higher doses might produce further weight reduction if tested. Adverse events were predominantly gastrointestinal (nausea, diarrhoea, vomiting, constipation), dose-dependent, and mostly mild-to-moderate, consistent with the class profile seen across the broader retatrutide product category.
A second Phase 2a study (Sanyal et al. 2024, Nature Medicine) reported significant reductions in hepatic fat fraction and liver enzymes in MASLD/MASH cohorts. This extends the mechanistic case for the glucagon arm beyond pure weight endpoints and into metabolic research applications targeting body composition and energy expenditure.
Timeline of disclosed clinical milestones
| Date | Milestone |
|---|---|
| 26 June 2023 | NEJM Phase 2 obesity results published (NCT04881760) |
| 2024 | Nature Medicine Phase 2a MASLD/MASH results (Sanyal et al.) |
| 2024–2026 | Phase 3 clinical trial status: no NCT-registered Phase 3 trial publicly indexed; no interim Phase 3 data published or presented at major congresses |
No regulatory approval for retatrutide has been granted by any authority globally as of March 2026. No head-to-head trial against the dual agonist used in the Body Pharm Tirzepatide 30 Pen has been registered. Any literature predating the 2023 NEJM disclosure should be treated as preliminary and potentially superseded once Phase 3 readouts enter the public record.
HD Labs Product Specifications
The HD Labs SKU under review is a 10 mg lyophilised peptide vial of retatrutide intended for in vitro and ex vivo research applications only, not for human or veterinary administration. Reconstitution with bacteriostatic water (0.9% benzyl alcohol) is standard for lyophilised GLP-1/GIP/glucagon tri-agonist peptides of this class. The working volume is selected by the investigator to suit the assay concentration required.
Storage follows published peptide chemistry convention. Unreconstituted vials held at −20 °C remain stable for long-term archival. Reconstituted aliquots are stable at 2–8 °C for short working windows and should be single-thaw to limit freeze-thaw degradation of the 39-residue acylated backbone shared with LY3437943.
HD Labs markets the vial as research-grade. No manufacturer-level HPLC purity figure or downloadable batch chromatogram is published in indexed 2024–2026 sources for HD Labs retatrutide SKUs. Procurement officers should request the lot-specific Certificate of Analysis (CoA) directly before release to protocol. For comparator-grade benchmarks, third-party research suppliers specify >99% purity by HPLC-MS on equivalent 10 mg retatrutide vials.
Domestic orders ship tracked and discreetly packaged within South Africa, with checkout secured via standard TLS payment processing. Researchers cross-referencing dual-agonist controls can source the Body Pharm Tirzepatide 30 Pen from the same catalogue, or browse the full retatrutide product category for alternative vial strengths. For research use only.
Buying Retatrutide in South Africa: What Researchers Should Know
Retatrutide is not a SAHPRA-registered medicine in South Africa as of 2026 and is supplied strictly as a research chemical, not as a therapeutic product. SAHPRA's publicly available registers list other GLP-1 receptor agonists such as liraglutide and semaglutide as Schedule 4 prescription medicines. No registration entry, Section 21 authorisation, or scheduling determination has been published for retatrutide (LY3437943). Supply therefore falls outside the medicine-registration regime of the Medicines and Related Substances Act 101 of 1965, and every compliant local listing carries explicit research-use-only labelling.
Institutional procurement officers should confirm that their ethics committee, biosafety officer, and internal SOPs permit the use of unregistered research chemicals before raising a purchase order. University-based investigators in particular should document the in vitro or ex vivo protocol scope. No South African university or CSIR group has publicly registered a triple-agonist research programme that could serve as institutional precedent.
JCSG.org ships the HD Labs vial domestically within South Africa with tracked, discreetly packaged delivery and standard secured checkout. ZAR pricing is displayed on the live product page rather than quoted here, since vial-level pricing in the local market shifts with import and exchange-rate cycles. Researchers comparing dual versus triple agonism can cross-reference the Body Pharm Tirzepatide 30 Pen or review the wider retatrutide product category for alternative vial strengths.
Related Peptides for Metabolic Research
Researchers comparing retatrutide against narrower mechanism-of-action profiles can source several directly relevant compounds from sibling pages within the same retatrutide product category catalogue on this site.
Tirzepatide is the closest mechanistic comparator, a dual GLP-1/GIP agonist that isolates the contribution of glucagon receptor activation when run alongside retatrutide. The Body Pharm Tirzepatide 30 Pen suits shorter dose-ranging protocols, while the Body Pharm Tirzepatide 60 Pen supports extended chronic-dosing models.
Semaglutide is a GLP-1 mono-agonist that provides the single-receptor baseline for any comparative tri-agonist study. The Body Pharm Semaglutide 6 Pen is the standard reference arm for receptor-isolation work.
Tesamorelin is a growth-hormone-releasing-factor analogue used in body composition research where the question concerns lipolysis driven by the GH/IGF-1 axis rather than incretin signalling, a non-overlapping comparator to retatrutide.
AOD-9604 is a synthetic fragment of human growth hormone (residues 176–191) used in lipolysis-focused models where researchers want adipose-tissue effects decoupled from glucose-regulatory pathways entirely.
Frequently Asked Questions
How does retatrutide differ from tirzepatide?
Retatrutide and tirzepatide differ by one receptor target: retatrutide is a triple agonist at GLP-1, GIP, and glucagon receptors, while tirzepatide is a dual GLP-1/GIP agonist. The added glucagon component in retatrutide is hypothesised to drive higher energy expenditure. That hypothesis is supported by the approximately 24% mean weight reduction at 48 weeks observed at the 12 mg dose in Jastreboff et al. 2023 (NEJM Phase 2 trial), which exceeds the approximately 22.5% seen with tirzepatide at its top dose. Researchers running comparative protocols typically pair an HD Labs retatrutide vial against the Body Pharm Tirzepatide 30 Pen to isolate the glucagon contribution.
Is retatrutide approved in South Africa?
No. Retatrutide (LY3437943) does not appear on SAHPRA's register of approved human medicines as of 2026. Locally branded vials within the retatrutide product category are supplied strictly as research chemicals labelled "not for human use" under the Medicines and Related Substances Act 101 of 1965.
What does 10 mg mean for a research vial?
The 10 mg figure refers to the total mass of lyophilised retatrutide peptide in the sealed vial before reconstitution. It is a stock quantity, not a dose. Researchers calculate working concentrations by adding a defined volume of bacteriostatic water.
How should retatrutide be stored after reconstitution?
Reconstituted retatrutide should be kept refrigerated at 2–8 °C and protected from light, consistent with standard lyophilised GLP-1 analogue handling. Unreconstituted vials are typically stored at −20 °C for long-term stability.
What phase of clinical trials is retatrutide in as of 2026?
Phase 2. No Phase 3 programme for LY3437943 is registered on ClinicalTrials.gov as of early 2026, and no interim Phase 3 data have been published or presented between January 2024 and March 2026.
Next Steps: Procurement and Protocol Planning
To raise a quotation or purchase order against the HD Labs Retatrutide 10mg SKU, open the live listing in the retatrutide product category and request the lot-specific Certificate of Analysis at checkout before release to protocol. Confirm with your institution's ethics committee and biosafety officer that your research scope complies with local handling requirements for unregistered research chemicals. If you are designing a comparative study, source the Body Pharm Tirzepatide 30 Pen as your dual-agonist control arm to isolate the glucagon-receptor contribution to your endpoints.
